Zobrazeno 1 - 10
of 184
pro vyhledávání: '"Shigeki, Motomura"'
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
Autor:
Naoto Tomita, Mami Tokunaka, Naoya Nakamura, Kengo Takeuchi, Junki Koike, Shigeki Motomura, Ko Miyamoto, Ako Kikuchi, Rie Hyo, Yoshihiro Yakushijin, Yasufumi Masaki, Soichiro Fujii, Takamasa Hayashi, Yoshiaki Ishigatsubo, Ikuo Miura
Publikováno v:
Haematologica, Vol 94, Iss 7 (2009)
Background Lymphoid neoplasm with 18q21.3/BCL2 and 8q24/MYC translocation to immunoglobulin (IG) genes as dual-hit lymphoma/leukemia is very rare and known to have a poor clinical outcome.Design and Methods To clarify the clinicopathological characte
Externí odkaz:
https://doaj.org/article/84210a61fe754cc8a773c6c8ae51bcf7
Autor:
Masataka Taguri, Yukako Hattori, Wataru Yamamoto, Chizuko Hashimoto, Yoshimi Ishii, Takuya Miyazaki, Hirotaka Takasaki, Takayoshi Tachibana, Katsumichi Fujimaki, Naoto Tomita, Yoshiaki Ishigatsubo, Taisei Suzuki, Yuki Nakajima, Yasufumi Ishiyama, Rika Sakai, Etsuko Yamazaki, Kazuho Miyashita, Kenji Matsumoto, Shigeki Motomura, Sachiya Takemura, Ayumi Numata
Publikováno v:
Leukemia Research. 39:1187-1191
Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::558cfd5a5a3faddb173b11fbb4d84658
https://doi.org/10.1016/j.leukres.2015.08.016
https://doi.org/10.1016/j.leukres.2015.08.016
Autor:
Yoshimi Ishii, Yoshiaki Ishigatsubo, Rika Sakai, Hirotaka Takasaki, Reina Watanabe, Shigeki Motomura, Hiroyuki Takahashi, Rika Kawasaki, Taishi Harada, Chizuko Hashimoto, Naoto Tomita, Wataru Yamamoto
Publikováno v:
Indian Journal of Hematology and Blood Transfusion. 31:346-351
We retrospectively analyzed the prognosis of patients with diffuse large B cell lymphoma (DLBCL) and a bulky mass at diagnosis. We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c11045f01b451cfa153c79a43588d6f0
https://doi.org/10.1007/s12288-014-0479-9
https://doi.org/10.1007/s12288-014-0479-9
Autor:
Shigeki Motomura, Ayumi Numata, Sachiya Takemura, Maki Hagihara, Daisuke Ishibashi, Naoto Tomita, Katsumichi Fujimaki, Hirotaka Takasaki, Hiroyuki Takahashi, Rika Ohshima, Kumiko Kishimoto, Reina Watanabe, Yoshiaki Ishigatsubo, Rika Sakai, Yoshimi Ishii, Satoshi Koyama, Yasufumi Ishiyama, Takayoshi Tachibana, Jun Taguchi, Chizuko Hashimoto
Publikováno v:
Leukemia & Lymphoma. 56:725-729
This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively studied 322 patients who achieved first complete remissio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2145b6d4bcb62d18556e4f5d2869d63
https://doi.org/10.3109/10428194.2014.931953
https://doi.org/10.3109/10428194.2014.931953
Autor:
Kiyohiko Hatake, Junko Iwasaki, Nobuyuki Mizunuma, Nozomu Fuse, Yasuhiro Yamanaka, Tatsuro Yamaguchi, Yasuo Hamamoto, Shigeki Motomura, Atsushi Ohtsu, Hiroshi Matsumoto, Toshihiko Doi, Mitsukuni Suenaga
Publikováno v:
The Journal of Clinical Pharmacology. 54:495-502
Previous reports of the influence of UGT1A1 gene polymorphisms on the pharmacokinetics of irinotecan metabolism have not assessed Asian patients treated with FOLFIRI plus bevacizumab for advanced and recurrent colorectal cancer. Twenty-one Japanese c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f98bd9b39a444a5cbd9c4d2dc06cf4f1
https://doi.org/10.1002/jcph.246
https://doi.org/10.1002/jcph.246
Autor:
Yuki Nakajima, Yoshiaki Ishigatsubo, Yoshimi Ishii, Rika Sakai, Yasufumi Ishiyama, Kenji Motohashi, Hirotaka Takasaki, Shigeki Motomura, Rika Kawasaki, Taisei Suzuki, Sachiya Takemura, Kumiko Kishimoto, Naoto Tomita, Chizuko Hashimoto, Shin Fujisawa, Satoshi Koyama, Eri Yamamoto, Yukako Hattori, Katsumichi Fujimaki, Hiroyuki Fujita
Publikováno v:
Leukemia & Lymphoma. 56:2750-2752
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) was first described by Isaacson and Wright in 1983 [1]. MALT lymphoma, an extranodal lymphoma composed of morp...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f05b96cee4fcc66579cc632f2196b4d5
https://doi.org/10.3109/10428194.2015.1010161
https://doi.org/10.3109/10428194.2015.1010161
Autor:
Katsumichi Fujimaki, Hirotaka Takasaki, Yuki Nakajima, Satoshi Koyama, Daisuke Ishibashi, Naoto Tomita, Chizuko Hashimoto, Megumi Itabashi, Shigeki Motomura, Yoshiaki Ishigatsubo, Reina Watanabe, Rika Ohshima, Yukako Hattori, Shin Fujisawa, Eri Yamamoto, Kenji Motohashi, Kazuho Miyashita, Rika Sakai, Etsuko Yamazaki, Hiroyuki Takahashi
Publikováno v:
European Journal of Haematology. 92:204-210
Objectives The tumor microenvironment, including tumor-infiltrating lymphocytes and myeloid-derived cells, is an important factor in the pathogenesis and clinical behavior of malignant lymphoma. However, the prognostic significance of peripheral lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9e82d42b0e365f6faf5ee49f7873e4
https://doi.org/10.1111/ejh.12221
https://doi.org/10.1111/ejh.12221
Autor:
Hirotaka Takasaki, Hideyuki Kuwabara, Shigeki Motomura, Naoto Tomita, Rika Sakai, Etsuko Yamazaki, Chizuko Hashimoto, Yoshiaki Ishigatsubo, Jun Taguchi, Kenji Matsumoto, Yoshimi Ishii, Atsuko Fujita, Hiroyuki Fujita, Wataru Yamamoto, Shin Fujisawa, Hideyuki Koharazawa
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 13:404-409
Background Although rituximab added to CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) is the standard chemotherapy for untreated DLBCL, its therapeutic effect is limited in younger patients with high-intermediate risk or high-risk disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a6e6ee63541e313356b4a92ed850ea
https://doi.org/10.1016/j.clml.2013.03.003
https://doi.org/10.1016/j.clml.2013.03.003
Autor:
Masao Kasahara, Yoshiaki Inayama, Kengo Takeuchi, Yoshiaki Ishigatsubo, Makiko Enaka, Koji Ogawa, Yoichi Kameda, Hiroyuki Takahashi, Naoto Tomita, Rika Ohshima, Shiro Matsuura, Seiji Sakata, Naoko Tsuyama, Yoshinori Takekawa, Noboru Onoda, Wataru Yamamoto, Shigeki Motomura, Chizuko Hashimoto
Publikováno v:
European Journal of Haematology. 90:286-290
Programmed cell death-1 (PD-1) is involved in one of the inhibitory pathways of the B7-cluster of differentiation (CD) 28 family; this pathway is known to be involved in the attenuation of T-cell responses and promotion of T-cell tolerance. PD-1 is k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3301255f92d1f2bf53eef5a26e4b1b93
https://doi.org/10.1111/ejh.12075
https://doi.org/10.1111/ejh.12075
Autor:
Rika Sakai, Yoshiaki Ishigatsubo, Naoto Tomita, Hideyuki Koharazawa, Eriko Ogusa, Hirotaka Takasaki, Jun Taguchi, Shin Fujisawa, Shigeki Motomura, Shiro Matsuura, Katsumichi Fujimaki, Hideyuki Kuwabara, Yoshimi Yamamoto, Wataru Yamamoto, Hiroyuki Fujita, Kumiko Kishimoto, Kazuho Miyashita
Publikováno v:
Journal of Clinical and Experimental Hematopathology. 53:121-125
Abstract 1630 Background: In almost all cases, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are CD20 positive. Since the introduction of rituximab (R), the outcome of the patients with FL or DLBCL has improved perceptively. Sinc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869658df4575b101f7d146752c6fdc03
https://doi.org/10.3960/jslrt.53.121
https://doi.org/10.3960/jslrt.53.121